Poly(Alkyloxyethylene-Lactate Phosphate) for Delivery of Doxorubicin: Synthesis and Characterization.

Doxorubicin / chemistry Drug Carriers / chemistry Humans Lactic Acid Phosphates Polyesters / chemistry
Polyphosphoesters amphiphilic polymers doxorubicin drug carriers drug delivery

Journal

Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988

Informations de publication

Date de publication:
Apr 2022
Historique:
received: 24 11 2021
revised: 08 02 2022
accepted: 18 02 2022
entrez: 29 3 2022
pubmed: 30 3 2022
medline: 5 4 2022
Statut: ppublish

Résumé

Serious side effects are associated with the use of doxorubicin. Nanoparticles as carriers for anticancer drugs are useful for reducing side effects and improving therapeutic effects. In this study, a polymer for preparing doxorubicin-containing nanoparticles was developed. Using a novel strategy, a biodegradable poly(oxyethylene glycol lactate H-phosphonate) based on dimethyl H-phosphonate and poly(ethylene glycol)-lactate (PEG-lactate) was synthesized. Poly(hexadecanyloxyethylene - lactate phosphate) was obtained via chlorination of poly(oxyethylene glycol - lactate H-phosphonate) with trichloroisocyanuric acid and the addition of 1-hexadecanol. The polymer was characterized by The results of Poly(hexadecanyloxyethylene - lactate phosphate) has potential as a drug carrier.

Sections du résumé

BACKGROUND/AIM OBJECTIVE
Serious side effects are associated with the use of doxorubicin. Nanoparticles as carriers for anticancer drugs are useful for reducing side effects and improving therapeutic effects. In this study, a polymer for preparing doxorubicin-containing nanoparticles was developed. Using a novel strategy, a biodegradable poly(oxyethylene glycol lactate H-phosphonate) based on dimethyl H-phosphonate and poly(ethylene glycol)-lactate (PEG-lactate) was synthesized.
MATERIALS AND METHODS METHODS
Poly(hexadecanyloxyethylene - lactate phosphate) was obtained via chlorination of poly(oxyethylene glycol - lactate H-phosphonate) with trichloroisocyanuric acid and the addition of 1-hexadecanol. The polymer was characterized by
RESULTS RESULTS
The results of
CONCLUSION CONCLUSIONS
Poly(hexadecanyloxyethylene - lactate phosphate) has potential as a drug carrier.

Identifiants

DOI: 10.21873/anticanres.15656 PMID: 35346998
pubmed: 35346998
pii: 42/4/1801
doi: 10.21873/anticanres.15656
doi:

Substances chimiques

Drug Carriers 0
Phosphates 0
Polyesters 0
Lactic Acid 33X04XA5AT
Doxorubicin 80168379AG

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1801-1811

Informations de copyright

Copyright © 2022 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Auteurs

Kanji Yoshikawa (K)

Faculty of Pharmaceutical Sciences, Tokyo University of Science, Chiba, Japan.

Teruki Nii (T)

Faculty of Pharmaceutical Sciences, Tokyo University of Science, Chiba, Japan.
Department of Applied Chemistry, Faculty of Engineering, Kyushu University, Fukuoka, Japan.
Graduate School of Systems Life Sciences, Kyushu University, Fukuoka, Japan.

Kolio Troev (K)

Center for Drug Delivery Research, Tokyo University of Science, Chiba, Japan.
Institute of Polymers, Bulgarian Academy of Sciences, Sofia, Bulgaria.

Kimiko Makino (K)

Faculty of Pharmaceutical Sciences, Tokyo University of Science, Chiba, Japan.
Center for Drug Delivery Research, Tokyo University of Science, Chiba, Japan.

Issei Takeuchi (I)

Faculty of Pharmaceutical Sciences, Tokyo University of Science, Chiba, Japan; itakeuchi@jiu.ac.jp.
Center for Drug Delivery Research, Tokyo University of Science, Chiba, Japan.
Faculty of Pharmaceutical Sciences, Josai International University, Chiba, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Glucides › Hétérosides › Aminosides › Anthracyclines › Daunorubicine › Doxorubicine › Poly(Alkyloxyethylene-Lactate Phosphate) for...
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Systèmes de délivrance de médicaments › Vecteurs de médicaments › Poly(Alkyloxyethylene-Lactate Phosphate) for...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Poly(Alkyloxyethylene-Lactate Phosphate) for...
questionsmedicales.fr › Composés chimiques organiques › Acides carboxyliques › Hydroxyacides › Lactates › Acide lactique › Poly(Alkyloxyethylene-Lactate Phosphate) for...
questionsmedicales.fr › Produits chimiques inorganiques › Composés du phosphore › Acides du phosphore › Acides phosphoriques › Phosphates › Poly(Alkyloxyethylene-Lactate Phosphate) for...
questionsmedicales.fr › Technologie, industrie et agriculture › Produits manufacturés › Matériaux biomédicaux et dentaires › Polymères › Polyesters › Poly(Alkyloxyethylene-Lactate Phosphate) for...